arsenic has been researched along with abt-199 in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jin, J; Naranmandura, H; Qian, JJ; Sun, WJ; Wang, QQ; You, LS; Zhu, HH | 1 |
| Jin, J; Naranmandura, H; Wang, HF; Wang, QQ; Zhao, JZ; Zhu, HH | 1 |
| Buettner, R; Burnett, J; Ghoda, L; Hoang, DH; Kuo, YH; Marcucci, G; Nguyen, LXT; Pullarkat, V; Rosen, ST; Valerio, M; Zhang, B | 1 |
3 other study(ies) available for arsenic and abt-199
| Article | Year |
|---|---|
Venetoclax and arsenic showed synergistic anti-leukemia activity in vitro and in vivo for acute myeloid leukemia with the NPM1 mutation.
Topics: Arsenic; Bridged Bicyclo Compounds, Heterocyclic; Cell Line; Drug Synergism; Humans; Leukemia, Myeloid, Acute; Mutation; Neoplasm Proteins; Nuclear Proteins; Nucleophosmin; Sulfonamides | 2020 |
Venetoclax for arsenic-resistant acute promyelocytic leukaemia.
Topics: Arsenic; Arsenic Trioxide; Arsenicals; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Promyelocytic, Acute; Oxides; Sulfonamides; Tretinoin | 2022 |
Arsenic Trioxide and Venetoclax Synergize against AML Progenitors by ROS Induction and Inhibition of Nrf2 Activation.
Topics: Antineoplastic Agents; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; NF-E2-Related Factor 2; Oxides; Reactive Oxygen Species; Recurrence; Sulfonamides | 2022 |